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The development of new biological therapeutics such as
neutralizing antibodies and small molecule inhibitors of recep-
tors signaling is revolutionizing many fields of medicine—and
creating new insights into normal biology. In particular,
inhibition of blood vessel growth has been vigorously
pursued in a number of fields, including oncology and
ophthalmology. To date, most experience with this class of
drugs centers on anti-vascular endothelial growth factor
(VEGF) agents such as a neutralizing antibody bevaci-
zumab and small molecule inhibitors of VEGF receptor-2
(VEGFR2). Anti-VEGF therapies have been spectacularly
successful for treatment of macular degeneration, and some-
what less so in the treatment of cancer. Hand in hand with
these advances is the emergence of new cardiac illnesses
directly related to the activity of these agents.
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VEGF is thought to play a key role in blood vessel
development. Vascular growth is so exquisitely VEGF
dependent that even a single copy deletion of the VEGF
gene itself, or of other genes in its signaling pathway, results
in early embryonic lethality (1,2). VEGF is also involved in
blood vessel growth in pathological states such as a “wet
form” of macular degeneration and growth of the tumor
vasculature, normal tissue repair processes such as wound
healing, and normal physiological events such as vasculature
growth in the uterus during the menstrual cycle (3).
Although these VEGF functions are well recognized,
until recently there has been little information about what
VEGF does in the normal adult vasculature. Some hints
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circulation of VEGF “traps” such as a circulating form of
VEGF receptor-1 (4) have been associated with decreased
VEGF bioavailability and increased blood pressure. Other
hints came from clinical trials of bevacizumab, where
frequent incidence of hypertension was noted. A recent
meta-analysis of trials enrolling 12,656 patients shows that
the therapy is associated with a 23.6% incidence of all-grade
and a 7.9% incidence of high-grade hypertension. Other
cardiovascular toxicities linked to anti-VEGF therapies
include increased risk of congestive heart failure, protein-
uria, arterial thromboembolic events, and hemorrhage (5).
This panoply of complications provides compelling evi-
dence for an important role played by VEGF in the
maintenance of the normal vasculature. Although much
effort over the last 2 decades has gone into anti- and
pro-angiogenic therapies, the very concept that a normal
vasculature needs to be actively “maintained” is new. Endo-
thelium is subjected to physical forces, such as shear and
circumferential stresses, and to a variety of hormones,
cytokines, and growth factors. In its own right, the endo-
thelium is also an active endocrine organ that secretes
numerous cytokines and growth factors, and it engages in
complex interactions with nonvascular cells that affect func-
tions of many organs, including the heart, brain, kidneys,
and liver. Such a busy life and heavy exposure to stressors
can be easily imagined to lead to injury requiring replace-
ment. Yet data from numerous laboratories show very low
basal level of endothelial cell proliferation in the normal
vasculature. In the absence of ongoing replacement, main-
tenance of the existing endothelial cell stock takes on an
even larger importance.
Recent studies in mice have shown that withdrawal of
VEGF (6), and surprisingly, fibroblast growth factors (7),
can lead to deleterious alterations in the normal vascular
function and profound systemic consequences. The study by
Belcik et al. (8) in this issue of the Journal adds an important
element to our understanding of the role of VEGF in the
normal vasculature. The authors find that systemic therapy
with an anti-VEGF antibody in mice leads to increased
blood pressure, myocardial hypertrophy, and renal abnor-
malities, thus mimicking many side effects seen in clinical
trials.
Multiple theories have been advanced to explain in-
creased blood pressure following administration of systemic
anti-VEGF or VEGFR2 therapies. These include microvas-
cular rarefication (implying a decrease in vascular capacity),
increased arterial stiffness, reduction in nitric oxide (NO)
production, and increased expression of pro-hypertensive
agents such as endothelin-1. Belcik et al. convincingly show
that a substantial hypertensive response induced by a
5-week course of anti-VEGF antibody therapy is clearly not
due to changes in arterial stiffness. The authors also found
no evidence for a decrease in microvascular volume, but the
technique used for its assessment, contrast-enhanced ultra-
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changes. Nevertheless, it seems unlikely that a capillary
rarefication, unless very pronounced, would affect systemic
blood pressure. Perhaps the most interesting observation is
an increase in angiotensin II (Ang II) levels and the
improvement in blood pressure after ramipril treatment.
The increase in Ang II levels in this setting has not been
previously reported even though renal abnormalities, includ-
ing thrombotic microangiopathy, have been observed in
patients and in animal models of anti-VEGF therapy.
An important limitation of this study is the absence of
assessment of NO production. Endothelium is the major
source of NO under noninflammatory conditions, with
eNOS (NOS3) being the principle enzyme responsible for
its generation. VEGF is known to control eNOS expres-
sion, and it is certainly plausible that its absence may result
in decreased eNOS levels and/or reduced activation. Con-
sistent with this idea of partial eNOS suppression is the fact
that an eNOS gene knockout results in a more severe
increase in blood pressure than was observed in this study.
Unfortunately, eNOS dysfunction has never been conclu-
sively demonstrated in a VEGF deficiency setting. In the
current study, anti-VEGF treatment was associated with
reduced eNOS expression, whereas levels of activated eNOS
remained unchanged, suggesting, but not conclusively dem-
onstrating, no reduction in overall NO production.
In addition to hypertension, a number of other compli-
cations can arise due to VEGF absence. VEGF is required
for maintenance of glomerular podocytes, and their loss
results in the albuminuria observed with anti-VEGF agents
(9). In the central nervous system, VEGF absence has been
linked to depression (10). In the heart, VEGF plays a major
role in coupling coronary circulation to myocardial function.
Afterload-induced myocardial hypertrophy requires con-
comitant VEGF-driven coronary angiogenesis to maintain
myocardial perfusion (11), whereas expansion of the coro-
nary vasculature can induce myocardial hypertrophy even in
the absence of a physical stimulus (12). Myocardial dysfunc-
tion observed in the present study and in the settings of
anti-VEGF therapy is likely the result of disruption of this
balance.
Finally, it is interesting to draw a parallel between the
now-emerging field of cardio-oncology and the field of
restenosis in the 1990s. The emergence of restenosis,
essentially a new disease brought about by the development
of intravascular devices, as an important clinical problem
became the catalyst for an unprecedented growth of cardio-
vascular molecular biology. This not only led to the discov-
ery of treatment for restenosis, but equally importantly,
broadened the scope of traditional cardiovascular research,
brought new minds and new technologies into the field,facilitated the development of many new therapies, and in
the process, put molecular cardiovascular research on an
equal footing with such fields as endocrinology and oncol-
ogy, which transitioned to molecular cell biology earlier
than cardiology. Now the introduction of new types of
biologics into cancer treatment protocols has led to the
appearance of new cardiovascular diseases that can be
traced, not to “off-target” effects of these drugs, but very
much to their “on-target” activity. This will undoubtedly
lead to a new surge of interest in basic cardiovascular
biology, bring new minds and technologies to the field, and
will further advance science and medicine. A larger picture
is that these 2 paradigms show how translational research
frequently works in real life—a therapeutic advance that
leads to a new and unexpected complication that in turn
requires deeper understanding of biology that can be then
used to solve new clinical problems.
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